in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Alvogen acquires Korean Dream Pharma for $187 million
August 6, 2014 | Natasha Alperowicz
Alvogen (Pine Brook, NJ), a privately owned pharmaceuticals company focused on developing, manufacturing, and distributing generic, OTC, and biosimilar products, announced today that it is acquiring Dream Pharma, a South Korean company, for $187 million in cash. Dream will be acquired through Alvogen’s Asian subsidiaries and, on completion, will create one of the largest generic pharmaceutical companies in South Korea. The transaction represents a significant milestone in Alvogen’s stated ambition to become one of the top five regional players in the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee